322 related articles for article (PubMed ID: 32553643)
21. Construction of calcium carbonate-liposome dual-film coated mesoporous silica as a delayed drug release system for antitumor therapy.
Wang Y; Zhao K; Xie L; Li K; Zhang W; Xi Z; Wang X; Xia M; Xu L
Colloids Surf B Biointerfaces; 2022 Apr; 212():112357. PubMed ID: 35101825
[TBL] [Abstract][Full Text] [Related]
22. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
[TBL] [Abstract][Full Text] [Related]
23. pH and redox dual stimulate-responsive nanocarriers based on hyaluronic acid coated mesoporous silica for targeted drug delivery.
Lin JT; Du JK; Yang YQ; Li L; Zhang DW; Liang CL; Wang J; Mei J; Wang GH
Mater Sci Eng C Mater Biol Appl; 2017 Dec; 81():478-484. PubMed ID: 28888000
[TBL] [Abstract][Full Text] [Related]
24. Preparation and in-vitro evaluation of mesoporous biogenic silica nanoparticles obtained from rice and wheat husk as a biocompatible carrier for anti-cancer drug delivery.
Porrang S; Rahemi N; Davaran S; Mahdavi M; Hassanzadeh B
Eur J Pharm Sci; 2021 Aug; 163():105866. PubMed ID: 33957220
[TBL] [Abstract][Full Text] [Related]
25. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
27. Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles.
Lin JT; Liu ZK; Zhu QL; Rong XH; Liang CL; Wang J; Ma D; Sun J; Wang GH
Colloids Surf B Biointerfaces; 2017 Jul; 155():41-50. PubMed ID: 28407530
[TBL] [Abstract][Full Text] [Related]
28. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract][Full Text] [Related]
29. Dual-responsive mesoporous silica nanoparticles coated with carbon dots and polymers for drug encapsulation and delivery.
Li X; Hu S; Lin Z; Yi J; Liu X; Tang X; Wu Q; Zhang G
Nanomedicine (Lond); 2020 Oct; 15(25):2447-2458. PubMed ID: 32945224
[No Abstract] [Full Text] [Related]
30. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity.
Li J; Du X; Zheng N; Xu L; Xu J; Li S
Colloids Surf B Biointerfaces; 2016 May; 141():374-381. PubMed ID: 26878288
[TBL] [Abstract][Full Text] [Related]
31. Amphiphilic hyperbranched polyester coated rod mesoporous silica nanoparticles for pH-responsive doxorubicin delivery.
Bafkary R; Ahmadi S; Fayazi F; Karimi M; Fatahi Y; Ebrahimi SM; Atyabi F; Dinarvand R
Daru; 2020 Jun; 28(1):171-180. PubMed ID: 32006342
[TBL] [Abstract][Full Text] [Related]
32. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
Wei Y; Gao L; Wang L; Shi L; Wei E; Zhou B; Zhou L; Ge B
Drug Deliv; 2017 Nov; 24(1):681-691. PubMed ID: 28414557
[TBL] [Abstract][Full Text] [Related]
33. Host-guest fabrication of dual-responsive hyaluronic acid/mesoporous silica nanoparticle based drug delivery system for targeted cancer therapy.
Lu J; Luo B; Chen Z; Yuan Y; Kuang Y; Wan L; Yao L; Chen X; Jiang B; Liu J; Li C
Int J Biol Macromol; 2020 Mar; 146():363-373. PubMed ID: 31911174
[TBL] [Abstract][Full Text] [Related]
34. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract][Full Text] [Related]
35. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
36. Tumor targeted delivery of umbelliferone via a smart mesoporous silica nanoparticles controlled-release drug delivery system for increased anticancer efficiency.
Kundu M; Chatterjee S; Ghosh N; Manna P; Das J; Sil PC
Mater Sci Eng C Mater Biol Appl; 2020 Nov; 116():111239. PubMed ID: 32806268
[TBL] [Abstract][Full Text] [Related]
37. Multistage pH-responsive mesoporous silica nanohybrids with charge reversal and intracellular release for efficient anticancer drug delivery.
Yuan X; Peng S; Lin W; Wang J; Zhang L
J Colloid Interface Sci; 2019 Nov; 555():82-93. PubMed ID: 31377647
[TBL] [Abstract][Full Text] [Related]
38. Enzyme-responsive mesoporous silica nanoparticles for tumor cells and mitochondria multistage-targeted drug delivery.
Naz S; Wang M; Han Y; Hu B; Teng L; Zhou J; Zhang H; Chen J
Int J Nanomedicine; 2019; 14():2533-2542. PubMed ID: 31114189
[No Abstract] [Full Text] [Related]
39. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
[TBL] [Abstract][Full Text] [Related]
40. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
